References in periodicals archive ?
has rolled out a generic version of Uceris (budesonide) extended-release tablets, 9 mg.
Teva Pharmaceutical Industries announced the launch of a generic version of Uceris, budesonide, extended-release tablets, 9 mg, in the U.S.
For a mild flare-up, budesonide MMX (Uceris) is recommended.
Salix has a portfolio of 22 total products, including prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a near- term pipeline of innovative, new assets.
Salix has a leading gastrointestinal franchise with a portfolio of 22 products, including prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a late stage pipeline of new assets.
The product is a generic version of the company's Uceris, which is a glucocorticosteroid designed for the induction of remission in patients with active, mild to moderate ulcerative colitis, a form of inflammatory bowel disease.
Valeant Pharmaceuticals announced that the Arbitral Tribunal issued a decision, rendered on April 9, relating to the arbitration between Santarus and Valeant and Cosmo Technologies, the licensor of certain intellectual property rights in, and supplier of, Valeant's Uceris extended release tablets.
District Court for the District of Delaware ruled in favor of Teva's Abbreviated New Drag Application (ANDA) for a generic equivalent of Valeant Pharmaceuticals International's Uceris extended-release tablets (budesonide ER).
Salix has a portfolio of 22 total products, including well-known prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a near- term pipeline of innovative, new assets.
M2 PHARMA-October 10, 2014-Salix Pharmaceuticals receives approval for UCERIS from FDA
Dictionary browser ?
- UBV photometry
- Uccello Paolo
- Udmurt Autonomous Republic
- Udmurt Republic
Full browser ?
- úcelové digitálne mapy
- Ucenicki Dom Luke Botica